Natco Pharma Ltd
Natco Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12). For fiscal year 2026, Natco expects revenue around INR 4,300 crores and PAT between INR 1,280-1,300 crores (Page 12). - Emerging markets, including Brazil and Middle East, along with Adcock profit consolidation, are anticipated to drive future growth (Page 17). - The U.S.
From Natco Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12).
- Emerging markets (Middle East, Brazil) and Adcock profit consolidation expected to drive growth in export revenue (Page 17).
- Domestic Indian market expected to grow over 20% in the next year, driven primarily by semaglutide (Page 12).
- U.S. market: Several ANDA approvals and product launches, including first-to-file/shared first-to-file, expected in the next 12 months, contributing to growth (Page 16).
- Base business expected to stabilize in H2 FY26; new product launches will increment growth (Page 16).
2 more points from Natco Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Natco Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No explicit current capital expenditure or strategic investment details were disclosed in the call.
- The company is actively pursuing 2-3 acquisition targets, focusing on emerging markets and established brand businesses to supplement portfolio growth.
- Rajeev Nannapaneni mentioned a preference for acquisitions outside India due to better returns despite currency and political risks.
- They currently have enough cash (approx. INR2,500 crores net) post Adcock acquisition and prefer preserving cash for large acquisitions rather than buybacks.
- Financing for large acquisitions may be a mix of cash, debt, and equity depending on the size and circumstances.
2 more points from Natco Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Natco Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Natco Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Natco Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹647 Cr, net profit ₹151 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Natco Pharma Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Natco Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Natco Pharma Ltd Q3 FY26 results?
Anticipated revenue for fiscal 2026 is around INR 4,300 crores, based on Q3 and Q4 projections (Page 12). For fiscal year 2026, Natco expects revenue around INR 4,300 crores and PAT between INR 1,280-1,300 crores (Page 12). - Emerging markets, including Brazil and Middle East, along with Adcock profit consolidation, are anticipated to drive future growth (Page 17). - The U.S.
What is Natco Pharma Ltd share price analysis?
Natco Pharma Ltd currently shows a neutral. The stock trades at a P/E of 11.6 with a market cap of ₹16,434 Cr. Investors should review the full earnings analysis for detailed insights.
Is Natco Pharma Ltd planning capital expenditure?
No explicit current capital expenditure or strategic investment details were disclosed in the call. - The company is actively pursuing 2-3 acquisition targets, focusing on emerging markets and established brand businesses to supplement portfolio growth. - Rajeev Nannapaneni mentioned a preference for acquisitions outside India due to better returns despite currency and political risks. - They currently have enough cash (approx.
Keep Natco Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.